Lymphocryptovirus Infections – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Lymphocryptovirus Infections – Drugs In Development, 2023’, provides an overview of the Lymphocryptovirus Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Lymphocryptovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lymphocryptovirus Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Lymphocryptovirus Infections
- The report reviews pipeline therapeutics for Lymphocryptovirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lymphocryptovirus Infections therapeutics and enlists all their major and minor projects
- The report assesses Lymphocryptovirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lymphocryptovirus Infections
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lymphocryptovirus Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lymphocryptovirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AlloVir IncAntengene Corp Ltd
Atara Biotherapeutics Inc
Baylor College of Medicine
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Calder Biosciences Inc
Cancer Research UK
Centre National de la Recherche Scientifique
Chengdu WestGene Biopharma Co Ltd
Children's Hospital Los Angeles
Children's National Hospital
Children's National Research Institute
Children's Research Institute
China Immunotech Co Ltd
Citranvi Biosciences LLC
Codiak BioSciences Inc
Dana-Farber Cancer Institute Inc
Dultech Advanced Sciences
Eutilex Co Ltd
Fred Hutchinson Cancer Research Center
Galenbio Ltd
Geneius Biotechnology Inc
George Papanicolaou Hospital
Grid Biosciences Hong Kong Ltd
Helmholtz Center Munich German Research Center for Health and Environment GmbH
iCELL Biotechnology Co Ltd
Immunotech Biopharm Ltd
Incyte Corp
Innovent Biologics Inc
Istituto Giannina Gaslini
Jiangsu Hengrui Medicine Co Ltd
Lion TCR Pte Ltd
Ludwig-Maximilians-University Munich
ManysmarT Therapeutics Inc
Medical College of Wisconsin
Merck & Co Inc
Moderna Inc
Nanjing Gulou Hospital
Nanjing Medical University Hospital 2
Nantes University Hospital
National University of Singapore
NexImmune Inc
Omeros Corp
Oxford Vacmedix UK Ltd
Peking University People's Hospital
QIMR Berghofer Medical Research Institute
Replicate Bioscience Inc
Savoy Pharmaceuticals Inc
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shanghai YaKe Biotechnology Co Ltd
Shenzhen Geno-Immune Medical Institute
Stemirna Therapeutics Ltd
SymBio Pharmaceuticals Ltd
The Chinese University of Hong Kong
The National Institute of Allergy and Infectious Diseases
U.S. National Institutes of Health
University College London
University of Pittsburgh
University of Queensland
University of Texas MD Anderson Cancer Center
University of Toronto
Valneva SE
Vernagen Inc
Viracta Therapeutics Inc
Vironika LLC
ViroStatics SRL
Western Sydney Local Health District (Australia)
Wistar Institute